1. bookVolume 53 (2015): Issue 3 (September 2015)
Journal Details
License
Format
Journal
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo

Rapid fecal calprotectin testing predicts mucosal healing better than C-reactive protein and serum tumor necrosis factor α in patients with ulcerative colitis

Published Online: 14 Oct 2015
Page range: 253 - 260
Received: 31 May 2015
Journal Details
License
Format
Journal
First Published
30 Mar 2015
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo
Abstract

Background and Aims. Serum and fecal biomarkers have been used as noninvasive methods for assessing disease activity in ulcerative colitis. C-reactive protein, serum tumor necrosis factor-α and fecal calprotectin are among the most promising such biomarkers. However, their role in the management of ulcerative colitis patients remains to be clarified. We aimed to evaluate the accuracy of C-reactive protein, fecal calprotectin and tumor necrosis factor-α in detecting clinical and endoscopic activity and predicting disease outcome.

Methods. A cohort of ulcerative colitis patients was prospectively evaluated for clinical and endoscopic disease activity using the Mayo score. Serum C-reactive protein and tumor necrosis factor-α levels were measured and a point-of-care method was used for determining Calprotectin levels.

Results. Fifty-three patients with ulcerative colitis were followed for a median of 12 months. Fecal calprotectin and C-reactive protein levels were significantly higher in patients with clinically active disease at baseline, but only calprotectin levels correlated with endoscopic activity. Calprotectin values over 300 μg/g had 60% sensitivity and 90% specificity for detecting active endoscopic disease and 61% sensitivity and 89% specificity for predicting mucosal healing.

Conclusion. Rapid calprotectin testing is a better predictor of mucosal healing than serum biomarkers and it could improve the management of ulcerative colitis patients by decreasing the need for invasive investigations.

Keywords

1. CIOFFI M, ROSA AD, SERAO R, et al. Laboratory markers in ulcerative colitis: Current insights and future advances. World J Gastrointest Pathophysiol. 2015; 6(1):13-22.Search in Google Scholar

2. MENDOZA JL, ABREU MT. Biological markers in inflammatory bowel disease: practical consideration for clinicians.Gastroenterol Clin Biol. 2009; 33 Suppl 3:S158.Search in Google Scholar

3. HENRIKSEN M, JAHNSEN J, LYGREN I, et al. C-reactive protein a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut. 2008; 57(11):1518-23.Search in Google Scholar

4. VAN RHEENEN PF, VAN DE VIJVER E, FIDLER V. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341:c3369.Search in Google Scholar

5. VON ROON AC, KARAMOUNTZOS L, PURKAYASTHA S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102: 803-813.Search in Google Scholar

6. TRAVIS SP, FARRANT JM, RICKETTS C, et al. Predicting outcome in severe ulcerative colitis. Gut 1996; 38:905–910.Search in Google Scholar

7. BOSCHETTI G, GARNERO P, MOUSSATA D, et al. Accuracies of Serum and Fecal S100 Proteins (Calprotectin and Calgranulin C) to Predict the Response to TNF Antagonists in Patients with Crohn's Disease. Inflamm Bowel Dis. 2015; 21(2):331-6.Search in Google Scholar

8. KISS LS, SZAMOSI T, MOLNAR T, et al. Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease. Aliment Pharmacol Ther. 2011; 34(8):911-22.Search in Google Scholar

9. MOOIWEER E, SEVERS M, SCHIPPER ME, et al. Low fecal calprotectin predicts sustained clinical remission in inflammatory bowel disease patients: a plea for deep remission. J Crohns Colitis. 2015; 9(1):50-5.Search in Google Scholar

10. D'HAENS G, FERRANTE M, VERMEIRE S, et al. Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease. Inflamm Bowel Dis. 2012; 18(12):2218-24.Search in Google Scholar

11. SCHOEPFER AM, BEGLINGER C, STRAUMANN A, et al. Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes. Inflamm Bowel Dis 2009; 15: 1851-1858.Search in Google Scholar

12. SIPPONEN T, KÄRKKÄINEN P, SAVILAHTI E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008; 28: 1221-1229.Search in Google Scholar

13. FROSLIE KF, JAHNSEN J, MOUM BA, et al. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007; 133:412-22.Search in Google Scholar

14. COSTA F, MUMOLO MG, CECCARELLI L, et al. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut. 2005; 54(3):364-8.Search in Google Scholar

15. NAISMITH GD, SMITH LA, BARRY SJ, et al. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease. J Crohns Colitis. 2014; 8(9):1022-9.Search in Google Scholar

16. CESARO A, ANCERIZ N, PLANTE A, et al. An inflammation loop orchestrated by S100A9 and calprotectin is critical for the development of arthritis. PLoS One. 2012; 7(9): e45478.Search in Google Scholar

17. FEGHALI CA, WRIGHT TM. Cytokines in acute and chronic inflammation. Front Biosci. 1997 1; (2):d12-26.Search in Google Scholar

18. VERMEIRE S, VAN ASSCHE G, RUTGEERTS P.C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis. 2004; 10(5):661-5.Search in Google Scholar

19. VATAY A, BENE L, KOVÁCS A, et al. Relationship between the tumor necrosis factor alpha polymorphism and the serum C-reactive protein levels in inflammatory bowel disease. Immunogenetics. 2003; 55(4):247-52.Search in Google Scholar

20. COLOMBEL JF, RUTGEERTS P, REINISCH W, et al. Early mucosal healing with infliximab is associated with improved longterm clinical outcomes in ulcerative colitis. Gastroenterology 2011; 141:1194-201.Search in Google Scholar

21. FENG JS, YANG Z, ZHU YZ, et al. Serum IL-17 and IL-6 increased accompany with TGF-β and IL-13 respectively in ulcerative colitis patients. Int J Clin Exp Med. 2014; 7(12):5498-504.Search in Google Scholar

22. OWCZAREK D, CIBOR D, GŁOWACKI MK, et al. TNF-α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn's disease and ulcerative colitis. Pol Arch Med Wewn. 2012; 122(12):616-23.Search in Google Scholar

23. SCHROEDER KW, TREMAINE WJ, ILSTRUP DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317: 1625–9.Search in Google Scholar

24. VAN ASSCHE G, DIGNASS A, PANES J, et al. European Crohn's and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. J Crohns Colitis. 2010; 4(1):7-27Search in Google Scholar

25. DIGNASS A, ELIAKIM R, MAGRO F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis. 2012; 6(10):965-90.Search in Google Scholar

26. SCHOEPFER AM, VAVRICKA S, ZAHND-STRAUMANN N, et al. Monitoring infammatory bowel disease activity: clinical activity is judged to be more relevant than endoscopic severity or biomarkers. J Crohns Colitis 2012; 6:412-418.Search in Google Scholar

27. RODA G, CAPONI A, BENEVENTO M, et al. New proteomic approaches for biomarker discovery in inflammatory bowel disease. Inflamm Bowel Dis. 2010; 16(7):1239-46.Search in Google Scholar

28. FAUBION WA JR1, FLETCHER JG, O'BYRNE S, et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serumMMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging. Am J Gastroenterol. 2013; 108(12):1891-900.Search in Google Scholar

29. DE VOS M, LOUIS EJ, JAHNSEN J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013; 19(10):2111.Search in Google Scholar

30. SCHMIDT C, GIESE T, HERMANN E, et al. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis. 2007;13(1):65-70.Search in Google Scholar

31. DIONNE S, HISCOTT J, D'AGATA I et al. Quantitative PCR analysis of TNF-alpha and IL-1 beta mRNA levels in pediatric IBD mucosal biopsies. Dig Dis Sci. 1997; 42(7):1557-66.Search in Google Scholar

32. MARTÍNEZ-BORRA J, LÓPEZ-LARREA C, GONZÁLEZ S, et al. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease. Am J Gastroenterol. 2002; 97(9):2350-6.Search in Google Scholar

33. SYDORA MJ, SYDORA BC, FEDORAK RN. Validation of a point-of-care desk top device to quantitate fecal calprotectin and distinguish inflammatory bowel disease from irritable bowel syndrome. J Crohns Colitis. 2012; 6(2):207-14Search in Google Scholar

34. VOIOSU T, BENGUŞ A, DINU R, et al. Rapid fecal calprotectin level assessment and the SIBDQ score can accurately detect active mucosal inflammation in IBD patients in clinical remission: a prospective study. J Gastrointestin Liver Dis. 2014; 23(3):273-8.Search in Google Scholar

35. SCHOEPFER AM, BEGLINGER C, STRAUMANN A, et al. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn's disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105: 162-169.Search in Google Scholar

36. YOON JY, PARK SJ, HONG SP et al. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014; 59(4):829-37.Search in Google Scholar

37. SCHOEPFER AM, BEGLINGER C, STRAUMANN A, et al. Fecal calprotectin more accurately reflects endoscopic activity of ulcerative colitis than the Lichtiger Index, C-reactive protein, platelets, hemoglobin, and blood leukocytes. Inflamm Bowel Dis. 2013; 19(2):332-41.Search in Google Scholar

38. LEWIS JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology. 2011; 140(6):1817-1826.Search in Google Scholar

39. MARTÍNEZ-BORRA J, LÓPEZ-LARREA C, GONZÁLEZ S, et al. High serum tumor necrosis factorα are associated with lack of response to infliximab in fistulizing Crohn’s disease. Am J Gastroenterol 2002; 97(9):2350-6.Search in Google Scholar

40. OLSEN T, GOLL R, CUI G et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007; 42(11):1312-20.Search in Google Scholar

41. KOMATSU M, KOBAYASHI D, SAITO K. Tumor necrosis factor-alpha in serum of patients with inflammatory bowel disease as measured by a highly sensitive immuno-PCR. Clin Chem. 2001; 47(7):1297-301.Search in Google Scholar

42. RODRÍGUEZ-PERÁLVAREZ ML, GARCÍA-SÁNCHEZ V, VILLAR-PASTOR CM, et al. Role of serum cytokine profile in ulcerative colitis assessment. Inflamm Bowel Dis. 2012; 18(10):1864-71.Search in Google Scholar

43. DE VOS M, LOUIS EJ, JAHNSEN J, et al. Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy. Inflamm Bowel Dis. 2013; 19(10):2111-7.Search in Google Scholar

44. GARCÍA-SÁNCHEZ V, IGLESIAS-FLORES E, GONZÁLEZ R, et al. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? J Crohns Colitis. 2010; 4(2):144-52.Search in Google Scholar

Plan your remote conference with Sciendo